Nionyx Bio Launches with $4M Seed to Transform AAV Gene Therapy for Kidney Disease with Proprietary Capsid Platform and Pipeline

NEW YORK, NY — September 29, 2025 — Nionyx Bio, a precision focused gene therapy company developing a proprietary AAV capsid platform and pipeline for renal diseases, today announced its launch and the closing of $4 million in seed financing led by 2048 Ventures, with participation from New York Ventures (Empire State Development), White Mug Healthcare, AIN Ventures, and Pathway Bioventures.…